South Rampart Pharma Announces New Study in Neurobiology of Pain Demonstrating How SRP-001 Delivers Central, Non-Toxic Pain Relief

South Rampart Pharma Announces New Study in Neurobiology of Pain Demonstrating How SRP-001 Delivers Central, Non-Toxic Pain Relief

Study highlights novel epigenomic modulation in the central nervous system as a key mechanism for SRP-001's analgesic effects Data further supports SRP-001's unique positioning as a safer, non-opioid, non-toxic analgesic Initiation of Phase 2 clinical trials with SRP-001 for acute…